Clinical Trial

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-10-03; most recent amendment 2026-02-25.
Trial Details
NCT Number NCT06075030
Lead Sponsor Kind Pharmaceuticals LLC
Conditions Chemotherapy Induced Anemia
Enrollment 36 participants
Start Date 2027-12
Primary Completion 2027-12 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-27